NARDIL TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

PHENELZINE (PHENELZINE SULFATE)

Saadav alates:

SEARCHLIGHT PHARMA INC

ATC kood:

N06AF03

INN (Rahvusvaheline Nimetus):

PHENELZINE

Annus:

15MG

Ravimvorm:

TABLET

Koostis:

PHENELZINE (PHENELZINE SULFATE) 15MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

MONOAMINE OXIDASE INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0106952001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2022-10-04

Toote omadused

PRODUCT MONOGRAPH
Pr
NARDIL
*
Phenelzine Sulfate Tablets USP
15 mg
ANTIDEPRESSANT
Searchlight Pharma Inc.
1600 Notre-Dame West, suite 312
Montreal, Quebec
H3J 1M1
Submission Control No.: 267161
Date of Preparation:
OCT
4,
2022
2
PRODUCT MONOGRAPH
NAME OF DRUG
Pr
NARDIL
*
Phenelzine Sulfate Tablets USP
15 mg
PHARMACOLOGICAL CLASSIFICATION
Antidepressant
ACTIONS AND CLINICAL PHARMACOLOGY
NARDIL (phenelzine sulfate) is a potent monoamine oxidase (MAO)
inhibitor. Monoamine oxidase is a
complex enzyme system, widely distributed throughout the body. Drugs
that inhibit monoamine oxidase in
the laboratory are associated with a number of clinical effects. Thus,
it is unknown whether MAO inhibition_ _
_per se_, other pharmacologic actions, or an interaction of both is
responsible for the clinical effects observed.
All the currently employed MAO inhibitors are readily absorbed after
oral administration. They are not given
parenterally. These drugs produce maximal inhibition of MAO in biopsy
samples from man within 5 to 10
days. However, although their biological activity is prolonged due to
the characteristics of their interaction
with the enzyme, their clinical efficacy appears to be reduced when
given less frequently than once daily. In
chronically treated phenelzine patients on 60 mg/day, steady-state
trough and peak levels are between 1 and
10 ng/mL.
INDICATIONS AND CLINICAL USE
NARDIL (phenelzine sulfate) is indicated in the treatment of depressed
patients clinically characterized as
"atypical", "nonendogenous" or "neurotic". These patients often have
mixed anxiety and depression and
phobic or hypochondriacal features. There is less conclusive evidence
of its usefulness for severely depressed
patients with endogenous features. NARDIL is indicated for patients
who have failed to respond to the drugs
more commonly used for these conditions.
CONTRAINDICATIONS
NARDIL (phenelzine sulfate) is contraindicated in patients with known
hypersensitivity to the drug or its
ingredients, with pheochromocytoma, congestive heart failur